Cullinan Therapeutics, Inc. (CGEM)

Quarterly Report Filed: 2026-05-07

The filing shows Cullinan Therapeutics has a diversified pipeline with multiple programs including CLN-617, CLN-978, CLN-049, CLN-619, Velinotamig, and Zipalertinib across various development stages, indicating multiple potential revenue catalysts.
The company maintains collaborative arrangements and licensing agreements (including with Genrix Biopharmaceutical Co., Ltd. and Pearl Taiho Pharma), suggesting partnerships to share development risks and potential commercialization pathways.
Investment portfolio includes diversified holdings across short-term and long-term instruments (US government securities, asset-backed securities, corporate notes) with fair value measurements tracked across multiple levels, indicating active cash management.
The filing references a sales agreement and subsequent events in April 2026, suggesting the company may be actively managing capital through various financing mechanisms to support ongoing R&D operations.

Current Report Filed: 2026-05-07

Cullinan Therapeutics announced Q1 2026 financial results on May 7, 2026, triggering disclosure requirements under Item 2.02 of Form 8-K.
The filing provides minimal substantive detail, with the full earnings announcement relegated to the press release (Exhibit 99.1) that is furnished but not filed, limiting regulatory liability for the company.
This is a routine quarterly earnings announcement with no indication of material agreements, leadership changes, or other significant corporate events beyond standard financial reporting.

Insider Trading Filed: 2026-05-06

Chief Scientific Officer Jennifer Michaelson executed a net sale of 8,000 shares (7,800 + 200) while simultaneously acquiring 4,000 shares through stock option exercise, indicating a net reduction in beneficial ownership from 174,844 to 166,844 shares.
The sales were executed under a Rule 10b5-1 trading plan established on August 7, 2025, suggesting these transactions were pre-planned and not reactive to current market conditions, which reduces concerns about negative insider sentiment.
Sales occurred at significantly higher prices ($14.60-$15.58 range) compared to the option exercise price of $4.30, representing substantial unrealized gains being monetized by company leadership.
The stock option vesting schedule shows 25% cliff vesting on July 4, 2020, with remaining shares in 36 monthly installments, indicating long-term incentive alignment, though the officer is now liquidating a portion of accumulated equity.

Annual Report Filed: 2026-03-10

Cullinan Therapeutics is a biopharmaceutical company focused on developing novel oncology therapies. The company has a diversified pipeline of early-stage programs, including CLN-049, CLN-418, and Zipalertinib, which target various types of cancer.
The company has established several strategic collaborations, including an agreement with Adimab and a license agreement with Genrix Biopharmaceutical Co. Ltd. These partnerships provide opportunities for further development and potential revenue generation.
Cullinan Therapeutics has a strong financial position, with $XXX million in cash and investments as of December 31, 2025. However, the company continues to incur significant research and development expenses as it advances its pipeline.

Current Report Filed: 2026-03-10

Cullinan Therapeutics reported its financial results for the year ended December 31, 2025, which could provide investors with insight into the company's recent performance and financial health.
The earnings release may contain information on key financial metrics, such as revenue, earnings, and guidance, which could help investors assess the company's current standing and future prospects.
Investors should closely review the details of the 8-K filing, including any material agreements, leadership changes, or other significant events, as these could have an impact on the company's valuation and investment outlook.

Insider Trading Filed: 2026-03-09

Insider Jennifer Michaelson, the Chief Scientific Officer, exercised 4,000 stock options and sold 8,000 shares, suggesting she is monetizing a portion of her equity holdings.
The sale of shares was executed pursuant to a pre-arranged 10b5-1 trading plan, indicating the transactions were planned in advance and not driven by immediate liquidity needs.
The reported transactions represent a relatively small portion of Michaelson's total beneficial ownership of 170,844 shares, suggesting she maintains a significant equity stake in the company.

Insider Trading Filed: 2026-02-26

Jennifer Michaelson, the Chief Scientific Officer, sold 1,780 shares of Cullinan Therapeutics, Inc. (CGEM) on February 25, 2026 at a weighted average price of $14.14 per share.
The sale was made pursuant to a 10b5-1 trading plan established on August 7, 2025, suggesting planned selling activity.
Following the reported transaction, Michaelson continues to hold 174,844 shares, maintaining a significant ownership stake in the company.

Insider Trading Filed: 2026-02-25

The reporting person, Jennifer Michaelson, who is the Chief Scientific Officer of Cullinan Therapeutics, Inc. (CGEM), has sold 5,353 shares of the company's common stock over the past two trading days, potentially indicating some insider selling activity.
The shares were sold at weighted average prices of $13.99 and $14.47, suggesting the reporting person may have been taking some profits on their holdings.
The reporting person still holds a significant number of shares (180,225) following the reported transactions, indicating they may maintain a substantial equity stake in the company.

Insider Trading Filed: 2026-02-25

The reporting person, Nadim Ahmed, who is the President and CEO of Cullinan Therapeutics, Inc. (CGEM), sold 13,515 shares of common stock on February 24, 2026 at a price of $14.47 per share.
The sale of shares appears to be for the purpose of covering personal income tax obligations upon the vesting of restricted stock units, as indicated in the filing.
Following the reported transaction, Nadim Ahmed continues to hold 390,803 shares of Cullinan Therapeutics' common stock directly.

Insider Trading Filed: 2026-02-25

Insider Jeffrey Alan Jones, the Chief Medical Officer, sold 4,582 shares of Cullinan Therapeutics (CGEM) at $14.47 per share on 2026-02-24. This sale was likely to cover personal income tax obligations upon vesting of his restricted stock units.
The reported transaction represents a relatively small portion of Jones' total beneficial ownership, which remains at 159,968 shares following the sale.
Insider sales can signal potential concerns about the company's outlook, but the timing and size of this transaction do not appear to be a significant cause for alarm.

Insider Trading Filed: 2026-02-25